Indian vaccine maker working on a range of low-priced products
Serum's offerings threaten to undercut brands from the world's biggest pharma firms
Mumbai
ASIA'S biggest vaccine maker is working on a string of new low-priced offerings that threaten to undercut brands from the world's biggest pharmaceutical companies.
Serum Institute of India Ltd, which makes vaccines injected in 65 per cent of the world's children, is targeting newer vaccines, including one for the human papillomavirus (HPV) that could be available in late 2018 and sell at a third of the price of Merck & Co's blockbuster Gardasil. Also in development are vaccines for types of severe diarrhoea and pneumonia.
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Sheng Siong Q1 net profit up 9.3% on higher revenue
Nestle sales growth sputters on US slump, vitamin snags
Hermes Q1 sales jump 17% on strong China demand
Cordlife’s independent auditor to retire after issuing disclaimer of opinion on FY2023 financials
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO
Cordlife customers push for legal action